Trends Mol MedJClub
Targeting the NAD(+)-PARP1-XRCC1 axis in ALS.
Trends in Molecular Medicine · · Review · Open access
Ibrahim, Hossain + more
Abstract ↗AI summary
The abstract is read at the publisher; the summary is JClub's.
The NAD+-PARP1-XRCC1 axis is positioned at the intersection of genome maintenance and metabolic control in ALS, linking oxidative DNA damage and NAD+ depletion to motor neuron degeneration.
- Why it matters: ALS is fatal and has few effective therapies, while oxidative DNA damage, impaired base excision/single-strand break repair, and progressive NAD+ depletion are linked to motor neuron degeneration. Targeting this intersection could address both DNA repair signaling and cellular bioenergetics.
- What they did: This review integrates mechanistic and translational evidence and proposes a staged framework using repurposable low-trapping PARP1 inhibitors plus NAD+ support, then CNS-directed RNA-lipid nanoparticle delivery of repair factors. It also suggests poly(ADP-ribose) and NAD+ metabolites as pharmacodynamic biomarkers.
- The result: The integrated evidence supports the NAD+-PARP1-XRCC1 axis as a therapeutic target in ALS and provides a translational plan with measurable biomarkers to guide development.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.
- Open access
Free. We’ll email you when a new paper cites this one or any other paper you follow on JClub — at most one email a day. Every email has a one-tap unsubscribe.